Search Within

Roisin Eilish O'Cearbhaill

Formats
  1. Meeting Abstract (128)
  2. Journal Article (125)
  3. Review (9)
  4. Editorial (6)
  5. Book Section (3)
  6. Guidelines (2)
  7. Correspondence (1)
Groups
  1. Department of Medicine (274)
  2. GDMT, Medicine (274)
  3. Gynecologic Medicine Service (274)
  4. Gynecology Disease Management Team (274)
  5. Hematologic Malignancies, Division of (274)
  6. Solid Tumor Oncology Division (274)

More Groups

People
  1. Carol Aghajanian (99)
  2. Alexia Iasonos (75)
  3. Qin Zhou (68)
  4. Rachel Grisham (68)
  5. Dennis Chi (67)
  6. William Tew (66)

More People

Years
  1. 2025 (16)
  2. 2024 (30)
  3. 2023 (43)
  4. 2022 (31)
  5. 2021 (25)
  6. 2020 (41)

More Years

Publications
  1. Gynecologic Oncology (91)
  2. Journal of Clinical Oncology (46)
  3. International Journal of Gynecological Cancer (39)
  4. Annals of Oncology (13)
  5. Gynecologic Oncology Reports (11)
  6. Clinical Cancer Research (9)

More Publications

Publishers
  1. Elsevier B.V. (102)
  2. American Society of Clinical Oncology (49)
  3. Lippincott Williams & Wilkins (40)
  4. Oxford University Press (14)
  5. American Association for Cancer Research (13)
  6. Nature Publishing Group (10)

More Publishers

Results (274)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The next generation of quality improvement at MSK: Turning chemotherapy process delays into chemo express
    Meeting Abstract

    Tota, J.; Levine, K.; Gordon, J.; Baldwin, A.; Wald, J.; Salvaggio, R.; Lee-Teh, M.; Freeswick, S.; O'Cearbhaill, R.; Reidy, D. L.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase I dose-escalation study of intraperitoneal (IP) cisplatin, IV/IP paclitaxel, IV bevacizumab, and oral olaparib for newly diagnosed adenxal carcinoma
    Meeting Abstract

    Konner, J. A.; Boucicaut, N. N.; O'Cearbhaill, R. E.; Zamarin, D.; Makker, V.; Sabbatini, P.; Tew, W. P.; Cadoo, K. A.; Grisham, R. N.; Aghajanian, C.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase II trial of enzalutamide in patients with androgen receptor positive (AR+) ovarian, primary peritoneal or fallopian tube cancer and one, two, or three prior therapies
    Meeting Abstract

    Grisham, R. N.; Giri, D. D.; Iasonos, A.; Zhou, Q.; Girshman, J.; McGrath, S. P.; O'Cearbhaill, R. E.; Sabbatini, P.; Tew, W. P.; Hyman, D. M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Somatic mutations in homologous recombination pathway genes in ovarian cancer
    Meeting Abstract

    Aghajanian, C.; DeLair, D.; Grisham, R. N.; Hensley, M. L.; Konner, J. A.; Makker, V.; O'Cearbhaill, R. E.; Sabbatini, P.; Soumerai, T.; Charen, A. S.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: A Surveillance, Epidemiology, and End Results cohort study, 2000-2013
    Journal Article

    Oseledchyk, A.; Leitao, M. M. Jr; Konner, J.; O'Cearbhaill, R. E.; Zamarin, D.; Sonoda, Y.; Gardner, G. J.; Roche, K. L.; Aghajanian, C. A.; Grisham, R. N.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer
    Journal Article

    Cowan, R. A.; O’Cearbhaill, R. E.; Zivanovic, O.; Chi, D. S.
    International Journal of Hyperthermia (2017)

    Fulltext@MSK | Save
  • Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
    Journal Article

    Sioulas, V. D.; Schiavone, M. B.; Kadouri, D.; Zivanovic, O.; Roche, K. L.; O'Cearbhaill, R.; Abu-Rustum, N. R.; Levine, D. A.; Sonoda, Y.; Gardner, G. J.; more...
    Gynecologic Oncology (2017)

    Fulltext@MSK | Save
  • Phase 1b of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with carboplatin (C) and paclitaxel (P) in recurrent platinum-sensitive ovarian cancer (OC)
    Meeting Abstract

    O'Cearbhaill, R. E.; McMeekin, D. S.; Mantia-Smaldone, G.; Gunderson, C.; Sabbatini, P.; Cattaruzza, F.; Fischer, M.; Kapoun, A. M.; Xu, L.; Dupont, J.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center
    Journal Article

    Mueller, J. J.; Kelly, A.; Zhou, Q.; Iasonos, A.; Long Roche, K.; Sonoda, Y.; O'Cearbhaill, R. E.; Zivanovic, O.; Chi, D. S.; Gardner, G. J.
    Gynecologic Oncology (2016)

    Fulltext@MSK | Save
  • Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center
    Journal Article

    Schlappe, B. A.; Mueller, J. J.; Zivanovic, O.; Gardner, G. J.; Roche, K. L.; Sonoda, Y.; Chi, D. S.; O'Cearbhaill, R. E.
    Gynecologic Oncology (2016)

    Fulltext@MSK | Save